EFFICACY AND SAFETY OF EXTIMIA®, A NEW PEGYLATED FILGRASTIM: RESULTS OF OPEN COMPARATIVE PHASE II CLINICAL TRIAL IN PATIENTS WITH BREAST CANCER RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY


O.V. Salafet 1, T.V. Chernovskaya 1 , L.P. Sheveleva 2 , A.V. Khorinko 3 , T.I. Prokopenko3, M.N. Nechayeva 4, O.N. Burdayeva 4 , M.P. Matrosova 5, N.V. Kovalenko 6 , I.A. Koroleva7, R.A. Ivanov 1

1 CJSC BIOCAD , Russia 2 Volgograd Regional Oncological Dispensary №1, Volgograd ; 3 Perm Regional Oncological Dispensary, Perm 4 Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk 5 Regional Oncological Dispensary of Nizhny Novgorod, Nizhny Novgorod 6 Stavropol Regional Clinical Oncological Dispensary, Stavropol 7 Samara Regional Oncological Dispensary, Samara
The article is dedicated to the prevention and treatment of neutropenia associated with the use of myelosuppressive chemotherapy in patients with malignant tumors, particularly breast cancer. For the prevention and treatment of neutropenia, recombinant preparations of human granulocyte colony stimulating factor are used for the last 20 years. The introduction of Extimia®, domestic preparation of pegylated filgrastim (empegfilgrastim) in clinical practice would provide more available modern drug against neutropenia, with advantages over pegylated filgrastim analogues, for the target population of patients with cancer receiving myelosuppressive chemotherapy.

About the Autors


L.P. Sheveleva - oncologist with higher qualification category at Volgograd Regional Oncological Dispensary №1; e-mail: ludmy@mail.ru


Similar Articles


Бионика Медиа